MedTrace Logo

Chepetsa TB - Reducing TB Among HIV-Infected Malawians

NCT01450085 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2017-08-18

No results posted yet for this study

Summary

The specific aims of this project are: (1) to compare the impact of using the routine screening and GeneXpert algorithms for TB case detection on Tuberculosis (TB)- and HIV-related outcomes; (2) to compare the impact of using the routine screening and GeneXpert algorithms for exclusion of TB prior to initiation of IPT and ART on TB- and HIV-related outcomes; and (3) to assess the relative cost-effectiveness of the routine screening and GeneXpert algorithms for TB case detection and exclusion of TB. The GeneXpert is a "disruptive technology"10 that could allow TB/HIV programs in resource-limited settings to leapfrog over solid and liquid culture-based TB diagnostic algorithms, and to remove a key barrier to scale up of ICF and IPT.

Conditions

Interventions

OTHER

GeneXpert

Point of care GeneXpert

OTHER

LED Microscopy

Point of care LED Microscopy

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Corbett, MD · Malawi Liverpool Wellcome Trust

  • David Dowdy, MD. PhD · Johns Hopkins Unviversity

  • Lawrence Moulton, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-12-31
Completion
2016-12-30

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450085 on ClinicalTrials.gov